IRIS
CORTI, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.745
EU - Europa 5.045
NA - Nord America 3.243
SA - Sud America 1.548
AF - Africa 129
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 15.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.088
RU - Federazione Russa 3.019
SG - Singapore 2.140
CN - Cina 1.858
BR - Brasile 1.284
HK - Hong Kong 735
SE - Svezia 687
VN - Vietnam 511
FR - Francia 269
RO - Romania 269
IT - Italia 266
DE - Germania 181
BD - Bangladesh 131
AR - Argentina 106
GB - Regno Unito 91
IN - India 91
FI - Finlandia 78
CA - Canada 66
EC - Ecuador 52
MX - Messico 52
ID - Indonesia 49
IE - Irlanda 44
ZA - Sudafrica 43
AT - Austria 38
IQ - Iraq 32
CO - Colombia 29
PY - Paraguay 28
JP - Giappone 27
NL - Olanda 24
PL - Polonia 24
TR - Turchia 23
MA - Marocco 18
EG - Egitto 15
ES - Italia 15
PK - Pakistan 15
UZ - Uzbekistan 15
MY - Malesia 13
PE - Perù 13
SA - Arabia Saudita 13
VE - Venezuela 13
CL - Cile 11
AE - Emirati Arabi Uniti 10
KE - Kenya 10
UY - Uruguay 10
LT - Lituania 9
NP - Nepal 9
TN - Tunisia 9
UA - Ucraina 9
AZ - Azerbaigian 8
IR - Iran 8
PH - Filippine 8
DO - Repubblica Dominicana 7
JM - Giamaica 7
AL - Albania 6
NG - Nigeria 6
DZ - Algeria 5
GE - Georgia 5
JO - Giordania 5
KR - Corea 5
KZ - Kazakistan 5
SN - Senegal 5
ET - Etiopia 4
PA - Panama 4
TT - Trinidad e Tobago 4
AU - Australia 3
BB - Barbados 3
BE - Belgio 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
GA - Gabon 3
HR - Croazia 3
KW - Kuwait 3
LB - Libano 3
SV - El Salvador 3
TH - Thailandia 3
TW - Taiwan 3
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CY - Cipro 2
DM - Dominica 2
GT - Guatemala 2
IL - Israele 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CD - Congo 1
CG - Congo 1
CH - Svizzera 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LY - Libia 1
Totale 15.706
Salva come PNG Salva come JPEG
Città #
Singapore 853
Hong Kong 728
Moscow 670
San Jose 529
Dallas 520
Ashburn 388
Shanghai 302
Hefei 287
Lawrence 266
Princeton 266
Lauterbourg 236
Ho Chi Minh City 183
Beijing 123
São Paulo 119
New York 106
Hanoi 99
Milan 85
Los Angeles 73
Helsinki 59
Santa Clara 52
Rio de Janeiro 45
Dublin 41
Nuremberg 41
Pune 34
Da Nang 30
Guangzhou 28
Boardman 24
Frankfurt am Main 24
Orem 24
The Dalles 24
Tokyo 24
Haiphong 22
Montreal 22
Curitiba 21
Denver 21
Quito 21
Hangzhou 20
London 20
Warsaw 20
Johannesburg 19
Munich 19
Brasília 18
Campinas 18
Chennai 18
Mexico City 18
Columbus 17
Dhaka 16
Guarulhos 16
Hải Dương 16
Rome 16
Stockholm 16
Vienna 16
Belo Horizonte 15
Brooklyn 14
Chicago 14
Phoenix 14
Salvador 14
Atlanta 13
Buffalo 13
Goiânia 13
Manchester 13
Poplar 13
Shenzhen 13
Turku 13
Asunción 12
Baghdad 12
Jakarta 12
Manaus 12
Porto Alegre 12
Santo André 12
Seattle 12
Tashkent 12
Thái Bình 12
Toronto 12
Fortaleza 11
Houston 11
San Francisco 11
Washington 11
Xi'an 11
Biên Hòa 10
Cape Town 10
Guayaquil 10
Boston 9
Cleveland 9
Lima 9
Montevideo 9
Recife 9
Ribeirão Preto 9
Sorocaba 9
Thái Nguyên 9
Wuxi 9
Can Tho 8
Cesano Boscone 8
Naples 8
Riyadh 8
Santiago 8
Amsterdam 7
Baku 7
Duque de Caxias 7
Ha Long 7
Totale 7.189
Salva come PNG Salva come JPEG
Nome #
A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer 385
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth 163
Hematopoietic stem-and progenitor-cell gene therapy for hurler syndrome 137
Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretion 129
Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome 127
Gold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer 127
An innovative platform approach for the development of ex-vivo gene therapies for the treatment of lysosomal storage diseases with skeletal involvement 118
A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins 117
A pilot phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma 115
Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods 111
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 111
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 107
Altered Chromogranin A Circulating Levels in Meniere’s Disease 106
Chromogranin A plasma levels predict mortality in COVID-19 104
Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging 104
CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study 103
Aminopeptidase N (CD13)-positive bone marrow-derived cells induce angiogenesis and tumor growth: A potential non-malignant immune cell target against cancer 100
A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on α5β1-targeted gold nanorods 99
[Activation and role of the tumor necrosis factor-alpha in congestive heart failure]. FT Attivazione e ruolo del fattore di necrosi tumorale alfa nello scompenso cardiaco congestizio. 94
A receptor-antibody sandwich assay for teicoplanin. 91
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 88
Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis 87
Affinity enhancement of complementary peptide recognition 87
Production and characterisation of human recombinant single chain urokinase-type plasminogen activator from mouse cells 86
Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models 86
Chromogranin-A production and fragmentation in patients with Takayasu arteritis. 86
Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma 86
A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator. 85
A stapled chromogranin A-derived peptide is a potent dual ligand for integrins αvβ6 and αvβ8 85
A new method for rapid and simple pregnancy detection using gold-labelled antibodies 84
Contrast enhanced photoacoustic detection of fibrillar collagen in the near infrared region-I 84
A rapid method for monitoring DNA labelling reactions with haptens. 84
A new chromogranin A-dependent angiogenic switch activated by thrombin 81
A novel aminopeptidase N/CD13 inhibitor selectively targets an endothelial form of CD13 after coupling to proteins 81
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α 80
Agents regulating vascular permeability 73
Quantification of Chromogranin A and Its Fragments in Biological Fluids 72
TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens 72
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours 69
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy 67
Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study 67
A Pilot Study on Continuous Infusion of 4% Albumin in Critically Ill Patients: Impact on Nosocomial Infection via a Reduction Mechanism for Oxidized Substrates 67
Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action 65
Tumor targeting with biotinylated tumor necrosis factor alpha: Structure-activity relationships and mechanism of action on avidin pretargeted tumor cells 65
Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity 65
Won't you come on in? How to favor lymphocyte infiltration in tumors 64
Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces and iron-deficient phenotype 64
Tumor necrosis factor-α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the successful treatment of patients with infliximab 64
Spatiotemporal regulation of tumor angiogenesis by circulating chromogranin a cleavage and neuropilin-1 engagement 64
Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif 63
Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides 63
Breaching the blood–brain tumor barrier for tumor therapy 63
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) 62
Identification of an epitope of tumor-necrosis-factor (TNF) receptor-type-1 (p55) recognized by a TNF-alpha-antagonist monoclonal-antibody 62
Mode of interaction between tumor-necrosis-factor-alpha and a monoclonal-antibody expressing a recurrent idiotype 61
Chromogranin A is preferentially cleaved into pro-angiogenic peptides in the bone marrow of multiple myeloma patients 61
Anti-idiotype monoclonal antibody directed against anti-TNF antibodies 61
Autocrine saturation of pro-urokinase receptors on human A431cells 61
T cells redirected to a minor histocompatibility antigen instruct intratumoral TNFα expression and empower adoptive cell therapy for solid tumors 61
The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells 60
Tumour necrosis factor: Strategies for improving the therapeutic index 60
IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines 60
Ways to improve tumor uptake and penetration of drugs into solid tumors 60
Chromogranin A and Its Fragments in the Critically Ill: An Expanding Domain of Interest for Better Care 59
Oxidative stress biomarkers and chromogranin A in uremic patients: Effects of dialytic treatment 59
Liposome-Mediated Therapy of Neuroblastoma 59
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells 58
Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy 58
Mechanism of suramin-induced deoligomerization of tumor-necrosis-factor-alpha 58
Cytokine conjugates (IL-12 –peptide conjugates) 58
Cromogranina A per uso come reagente in un metodo diagnostico o prognostico 58
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism 58
Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αvβ3 without Promoting Integrin Allosteric Activation 58
Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms 58
The elusive role of proton pump inhibitors in COVID-19: Can plasma Chromogranin A levels hold the key? 57
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer 57
Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability 57
Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha 57
Anti-urokinase monoclonal antibody, matrix bearing it, test method, biochemical test kits which use it. 57
Chromogranin A and the Tumor Microenvironment 57
Oxidation-induced structural changes of ceruloplasmin foster NGR-motifs deamidation that promote integrin binding and signaling 57
PCR amplification of antibody variable regions using primers that anneal to constant regions 56
Chromogranin A Regulates Tumor Self-Seeding and Dissemination 56
Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): assessment of severity in patients with sepsis. 56
Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications, and alternative roads 56
Monoclonal antibodies against the TNF type-I receptor, process for their production and use thereofAnticorpi monoclonali anti-recettore di tipo 1 del TNF alfa, procedimento per la loro produzione e loro uso 56
Receptor-antibody sandwich assay. 56
Oligomeric Tumor-necrosis factor alpha slowly converts into inactive forms at bioactive levels 56
Nanogold Functionalized With Lipoamide-isoDGR: A Simple, Robust and Versatile Nanosystem for αvβ3-Integrin Targeting 56
Structure-activity relationships of chromogranin A in cell adhesion - Identification of an adhesion site for fibroblasts and smooth muscle cells 55
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas 55
Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium? 55
Conversation galante: How the immune and the neuroendocrine systems talk to each other 55
Tumor-necrosis-factor (TNF)-alpha quantification by ELISA and bioassay - effects of TNF-alpha-soluble TNF-receptor (p55) complex dissociation during assay incubations 55
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 55
Regulation of tumor growth by circulating full-length chromogranin A 55
NF-kappa B-mediated regulation of urokinase gene expression by PMA and TNF-alpha in human A549 cells 55
Physiological levels of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity 55
Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors 54
Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin1-78 and rat CgA(1-64)) in the rat heart 54
Totale 7.705
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.249
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.249
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022111 0 0 0 70 0 7 7 5 2 2 1 17
2022/20231.296 604 245 115 3 2 138 42 67 64 5 5 6
2023/2024417 5 8 62 36 26 88 24 33 0 18 37 80
2024/20253.632 461 37 54 101 80 265 744 277 649 504 226 234
2025/202610.315 698 934 771 1.635 678 199 945 746 2.734 504 181 290
Totale 15.857